CD19 and neoplasm: The Schneck's group developed NPs, stimulating T cells to kill tumor cells, by coating a single NP with tumor cell-binding antibody (a-human CD19) and loaded antigen-specific T cell-binding peptide (MHC-binding peptide) 75.